Evidence map›Paper›PMID 34061599›Full record

ArticlemBio2021

A BMPR2/YY1 Signaling Axis Is Required for Human Cytomegalovirus Latency in Undifferentiated Myeloid Cells.

Emma Poole, Maria Cristina Carlan da Silva, Chris Huang, Marianne Perera, Sarah Jackson, Ian J Groves, Mark Wills, Amer Rana, John Sinclair

Open access · goldAbstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Dual Role of YY1 in HPV Life Cycle and Cervical Cancer Development.International journal of molecular sciences · 2022
    Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Emma PooleCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Maria Cristina Carlan da SilvaCenter for Natural and Humanities Sciences, Federal University of ABC (UFABC), São Bernardo do Campo, Brazil.
Chris HuangDepartment of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.
Marianne PereraCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Sarah JacksonCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Ian J GrovesCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Mark WillsCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Amer RanaDepartment of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.
John SinclairCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom.
University of Cambridge · GBUniversidade Federal do ABC · BR

Funding

British Heart Foundation CH/09/001/25945British Heart Foundation PG/14/31/30786British Heart Foundation SP/12/12/29836Department of HealthMedical Research Council MR/K021087/1Medical Research Council MR/S00081X/1
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) presents a major health burden in the immunocompromised and in stem cell transplant medicine. A lack of understanding about the mechanisms of HCMV latency in undifferentiated CD34

Indexed as

Host-Pathogen InteractionsSignal TransductionVirus LatencyBone Morphogenetic Protein Receptors, Type IICells, CulturedCytomegalovirusHumansInduced Pluripotent Stem CellsMyeloid CellsTHP-1 CellsYY1 Transcription FactorBMPR2 protein, humanBone Morphogenetic Protein Receptors, Type IIYY1 protein, humanYY1 Transcription FactorBMPR2human cytomegaloviruslatencystem cellsYY1

Identifiers

PMID34061599
PMCPMC8262994
OpenAlexW3165068306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.